NTx Appoints Edward Liddy, Former Chairman and CEO of Allstate Corporation, to Board of Directors

Mr. Liddy brings more than 30 years of executive leadership, IPO and private equity experience, and board involvement at Abbott Laboratories, AbbVie and Boeing to help guide the commercialization efforts of NTx

RIO RANCHO, New Mexico, January 20, 2022–(BUSINESS WIRE)–NTx, a bioinformatics and biofabrication company providing cellless continuous flow manufacturing solutions for medical products and materials sciences, today announced that Edward Liddy, the former Chairman and CEO of Allstate Corporation, joined its Board of Directors. As a member of the Board of Directors, Mr. Liddy will provide unparalleled strategic advice to help NTx on its journey to commercialization and drive rapid growth.

This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20220120005631/en/

Edward Liddy, the former chairman and CEO of Allstate Corporation, has joined NTx’s board of directors. (Photo: BusinessWire)

Currently, Liddy also sits on the board of AbbVie and 6K, and he previously served on the boards of 3M Corporation, Abbott Laboratories, Boeing, and Goldman Sachs.

During his career, Mr. Liddy led the 1995 spin-off of Allstate Corporation from Sears, Roebuck & Co, where he eventually became Chairman, President and Chief Executive Officer. Under his leadership, Allstate’s market value more than tripled thanks to rationalization initiatives led by Liddy. Following his retirement as chairman of Allstate in 2008, the Secretary of the U.S. Department of the Treasury requested that Mr. Liddy serve as interim president and CEO of American International Group, Inc. (AIG) for the financial crisis of 2008-2009, where he led one of the largest restructuring efforts in American corporate history.

“NTx is redefining and revolutionizing pharmaceutical manufacturing with a disruptive technology that will re-footprint, rapidly scale and reduce the cost of mRNA production, delivering quality products with its innovative cell-free system,” said Edward. Liddy. I look forward to working closely with the NTx team and other prominent board members to increase market traction and help fuel the global supply chain for vaccines and rapid-deployment therapies. . »

Mr. Liddy joins a board of directors comprised of renowned pharmaceutical and biotechnology industry leaders, including Andrew Weber, former US Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense; Charles McMillan, former director of the Los Alamos National Laboratory; Nancy Rurkowski, former executive at Bristol-Myers Squibb; Joseph Sullivan, Director of Operations at NTx; David Seldin, managing partner at Anzu Partners; Thomas Nickoloff, managing director at Camino Real Capital Partners; NTx co-founder and CTO, Dr. Michael Humbert; and NTx co-founder, CEO and CSO, Dr. Alex Koglin.

“We are privileged to have Mr. Liddy bring his decades of global business expertise and executive leadership skills to the NTx Board of Directors and we believe his guidance will play a vital role in helping the company gain commercial traction” , said Dr. Alex Koglin. “Along with the other members of our Board of Directors and the entire NTx team, Mr. Liddy will be invaluable as we work to advance medicine and improve patient access.”

For more information about NTx and its proprietary platform, please visit: https://www.ntxbio.com.

About NTx

NTx is a bioinformatics and biofabrication company advancing medical products and materials science with innovative, cell-free biofabrication solutions. The company markets its NTxpress®, NTxscribe® biomanufacturing systems and DruID bioinformatics platform for natural product discovery. NTx biosynthesis technology, which is designed for mRNA and proteins made in vitro, is completely defined as it is not dependent on cell lines. NTx’s biomanufacturing processes can easily be scaled to meet fluctuating supply needs so companies can scale up and streamline production while meeting changing global demand. For more information, please visit: https://www.ntxbio.com

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220120005631/en/


Kalyn Schieffer, kos@anzupartners.com

Comments are closed.